US equities |
META $620.19 ▼-1.64% MU $928.76 ▲+2.77% NVDA $217.94 ▲+0.90% TSLA $407.46 ▲+4.04% SPCX $148.58 ▲+1.14% AAPL $347.10 ▲+0.93% AMD $560.26 ▲+5.45% MSFT $531.33 ▼-0.24%
FinancialContent

Sana Biotechnology, Inc. - Common Stock (NQ:SANA)

2.470 +0.110 (+4.66%)
Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sana Biotechnology, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
From Pomerantz LLP
Via GlobeNewswire
News headline image
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
News headline image
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sana Biotechnology
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs ↗
 
Via Benzinga
News headline image
Sana Biotechnology, Inc. Stockholder News: Robbins LLP Reminds Investors of the Class Action Lawsuit Against SANA
From Robbins LLP
Via GlobeNewswire
News headline image
ROSEN, LEADING INVESTOR COUNSEL, Encourages Sana Biotechnology, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SANA
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Sana Biotechnology, Inc. and Certain Officers – SANA
From Pomerantz LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Sana Biotechnology, Inc. (NASDAQ: SANA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the Cowen 45th Annual Health Care Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Retail Traders Flocked To These 5 Biotech Stocks In January — Here’s Why ↗
Biotech remains a high-risk, high-reward sector, and this month’s top draws reflect retail’s appetite for stocks with major clinical and regulatory catalysts. 
Via Stocktwits
News headline image
There May Still Be Time to Get in on These 3 Trending Biotechs
Biotech firms as a group declined slightly in the last year amid a tough external environment, but these three companies could grow in 2025. 
Via MarketBeat
Topics ETFs Economy
News headline image
Biotech Breakthroughs: Sana Biotechnology (NASDAQ: SANA) Type 1 Diabetes, CS Diagnostics (OTCQB: CSDX) Cancer Therapy – CURR, TPET, PRSO, PNPN.V, EONR – Plus More Stocks Under $2 Inside See Now!
Via AB Newswire
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Sana Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Crude Oil Down 1%; US Weekly Jobless Claims Decline ↗
 
Via Benzinga
News headline image
AAR Posts Upbeat Results, Joins AngioDynamics, eBay, Cal-Maine Foods And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
US Stocks Down; Acuity Brands Posts Weak Revenue ↗
 
Via Benzinga
News headline image
Sana Biotechnology Stock Surges Over 200% On Wednesday - Here's Why ↗
Sana Biotechnology's first-in-human study shows UP421 pancreatic islet cells surviving and functioning in type 1 diabetes without immunosuppression. 
Via Benzinga
News headline image
Why Cal-Maine Foods Shares Are Trading Higher By 4%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at December 2024 Investor Conferences
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology Reports Third Quarter 2024 Financial Results and Business Updates
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday ↗
 
Via Benzinga
News headline image
Sana Biotechnology Announces Increased Focus on Type 1 Diabetes and B-cell Mediated Autoimmune Diseases with the Potential to Deliver Clinical Proof of Concept Data Across Multiple Studies in 2024 and 2025
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Sana Biotechnology to Present at the Goldman Sachs Cell Therapy Day Conference
From Sana Biotechnology, Inc
Via GlobeNewswire
News headline image
Casella Waste Systems, SES AI And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 Next >